申联生物
(688098)
| 流通市值：22.05亿 | | | 总市值：22.05亿 |
| 流通股本：4.11亿 | | | 总股本：4.11亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 105,113,241.13 | 138,282,087.67 | 40,943,383.71 | 44,975,592.99 |
| 应收票据及应收账款 | 315,111,042.23 | 272,296,695.34 | 313,401,464.68 | 273,974,180.85 |
| 应收账款 | 315,111,042.23 | 272,296,695.34 | 313,401,464.68 | 273,974,180.85 |
| 预付款项 | 1,174,527.45 | 1,174,854.8 | 1,800,675.71 | 2,089,732.63 |
| 其他应收款合计 | 3,575,043.05 | 3,841,461.41 | 4,827,710.44 | 3,086,477.72 |
| 存货 | 95,054,545.33 | 114,204,357.32 | 112,003,904.26 | 111,788,877.6 |
| 其他流动资产 | 59,659.39 | 56,515.38 | - | 0 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 581,043,452.61 | 570,361,006.28 | 605,299,685.32 | 598,290,313.62 |
| 非流动资产: | | | | |
| 长期股权投资 | 3,587,465.88 | 1,583,061.78 | 1,592,613.7 | 1,585,586.96 |
| 固定资产 | 638,076,048.22 | 651,514,304.45 | 646,043,036.12 | 658,334,632.32 |
| 在建工程 | 166,643,230.59 | 156,524,507.97 | 170,351,305.78 | 163,442,866.95 |
| 生产性生物资产 | 139,356.39 | 156,973.02 | 197,096.99 | 206,459.76 |
| 使用权资产 | 1,960,002.71 | 2,288,276.95 | 1,243,962.8 | 1,326,402.17 |
| 无形资产 | 104,970,938.58 | 107,169,376.83 | 104,561,537.75 | 93,599,128.04 |
| 开发支出 | 49,895,290.31 | 45,863,682.47 | 31,062,389.26 | 42,351,681.02 |
| 递延所得税资产 | 7,265,174.39 | 5,736,367.36 | 5,506,919.82 | 5,137,013.68 |
| 其他非流动资产 | 28,430,450 | 15,975,365.69 | 28,290,004.95 | 29,720,201.25 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,000,967,957.07 | 986,811,916.52 | 988,848,867.17 | 995,703,972.15 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,582,011,409.68 | 1,557,172,922.8 | 1,594,148,552.49 | 1,593,994,285.77 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 8,272,822.39 | 3,504,296.51 | 10,297,009.89 | 5,144,152.9 |
| 应付账款 | 8,272,822.39 | 3,504,296.51 | 10,297,009.89 | 5,144,152.9 |
| 合同负债 | 12,294,209.51 | 18,536,073.78 | 8,360,501.95 | 6,646,749.51 |
| 应付职工薪酬 | 13,664,396.02 | 9,323,464.54 | 7,949,402.98 | 18,220,162.92 |
| 应交税费 | 2,868,884.76 | 1,130,010.67 | 5,029,441.05 | 2,345,938.49 |
| 其他应付款合计 | 45,766,028.09 | 44,619,299.5 | 38,214,850.57 | 33,880,668.01 |
| 应付股利 | 553,005.07 | 1,879,743.4 | 518,946.62 | 518,946.62 |
| 一年内到期的非流动负债 | 520,132.8 | 563,038.28 | 329,873.24 | 333,813.77 |
| 其他流动负债 | 11,218,239.96 | 10,782,149.16 | 9,902,344.51 | 9,931,542.31 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 94,604,713.53 | 88,458,332.44 | 80,083,424.19 | 76,503,027.91 |
| 非流动负债: | | | | |
| 租赁负债 | 1,226,859.56 | 1,630,223.77 | 842,558.11 | 917,185.21 |
| 递延收益 | 10,431,336.79 | 10,810,295.56 | 9,269,254.25 | 9,488,213.03 |
| 递延所得税负债 | 73,508.46 | 14,252.24 | 10,729.71 | 17,884.8 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 11,731,704.81 | 12,454,771.57 | 10,122,542.07 | 10,423,283.04 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 106,336,418.34 | 100,913,104.01 | 90,205,966.26 | 86,926,310.95 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 410,644,000 | 410,644,000 | 410,644,000 | 410,644,000 |
| 资本公积 | 539,233,471.91 | 539,233,471.91 | 539,233,471.91 | 539,233,471.91 |
| 盈余公积 | 75,020,487.07 | 75,020,487.07 | 75,020,487.07 | 75,020,487.07 |
| 未分配利润 | 435,337,038.97 | 414,953,747.05 | 461,625,075.64 | 463,834,260.37 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,460,234,997.95 | 1,439,851,706.03 | 1,486,523,034.62 | 1,488,732,219.35 |
| 少数股东权益 | 15,439,993.39 | 16,408,112.76 | 17,419,551.61 | 18,335,755.47 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,475,674,991.34 | 1,456,259,818.79 | 1,503,942,586.23 | 1,507,067,974.82 |
| 负债和股东权益合计 | 1,582,011,409.68 | 1,557,172,922.8 | 1,594,148,552.49 | 1,593,994,285.77 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |